The pursuit for CJC-1295 in Jegun consistently ends with the same conclusion: research peptides are delivered through specialist online vendors, not brick-and-mortar outlets. The key implication for Jegun researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the framework for evaluating that quality is identical for researchers everywhere. Separating properly characterised CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide takes Jegun researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Jegun researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
The first step for any Jegun researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — commercial rankings reflect SEO budgets rather than product quality. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone provides no identity confirmation. Strong quality indicators beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Jegun
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bac water. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that proper COA verification addresses. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
